Loading stock data…
ANRO
$24.94-0.72 (-2.81%)
Market ClosedLast close May 1
Alto Neuroscience, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ANRO in the Healthcare sector is trading at $24.94. The stock is currently near its 52-week high of $28.44, remaining 87.4% above its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why ANRO maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$24.94
Potential Upside
5%
Whystock Fair Value$26.19
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$901.21M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.06
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-41.84%
Volume
Today's trading volume
207,730
Recent News
Top 1% Alto Neuroscience Plummets On Its Shocking Schizophrenia Miss
Alto Neuroscience deprioritized its lead asset Thursday, a treatment for cognitive impairment due to schizophrenia. The biotech stock tumbled.
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks declined late Thursday afternoon with the NYSE Health Care Index dropping 0.6% an
Update: Alto Neuroscience Shares Fall After Phase 2 Trial of ALTO-101 Yields Statistically Insignificant Data
(Updates with the latest stock movement in the headline and the first paragraph.) Alto Neuroscien
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM
Shares of Immunovant, Alto and Oric Pharmaceuticals fell this week on clinical trial updates. Elsewhere, Orca Bio’s cell therapy hit a delay and Korsana entered a reverse merger.
Alto Neuroscience CFO Nick Smith on Firm’s $120 Million Private Placement
Alto Neuroscience CFO Nick Smith joins Ashley Mastronardi on NYSE Live to discuss their firms $120 million private placement financing